Irish MedTech Innovators CroíValve and Lios Secure Significant European Funding
Dublin, Ireland – July 1, 2025 – Two pioneering Irish companies, CroíValve and Lios, have been awarded a substantial €18.75 million in funding from the prestigious European Innovation Council (EIC) Accelerator programme. This significant investment underscores the strength of Ireland’s medtech and life sciences sector and highlights the transformative potential of these innovative ventures on a European scale.
The EIC Accelerator is a highly competitive grant and equity funding instrument designed to support breakthrough innovations from small and medium-sized enterprises (SMEs) that have the potential to create new markets and disrupt existing ones. The selection process is rigorous, focusing on the novelty, market potential, and scalability of the proposed technologies, as well as the strength of the founding team.
CroíValve: Revolutionizing Cardiac Surgery
CroíValve, a company dedicated to improving the lives of patients with heart valve disease, has secured a significant portion of this funding. Their innovative technology aims to address the critical unmet need for less invasive and more effective treatments for tricuspid regurgitation, a debilitating condition affecting millions worldwide.
The company’s flagship solution is a novel, minimally invasive device designed to repair the tricuspid valve without the need for open-heart surgery. This approach promises to reduce patient recovery times, lower complication rates, and improve the overall quality of life for individuals suffering from this condition. The EIC funding will be instrumental in enabling CroíValve to advance its clinical trials, scale up manufacturing capabilities, and navigate the complex regulatory pathways towards market approval. This investment is a strong endorsement of the clinical need for their technology and the company’s ability to deliver a groundbreaking solution.
Lios: Advancing Ophthalmic Surgery
Lios, another Dublin-based innovator, is set to leverage its share of the EIC funding to further develop its cutting-edge ophthalmic solutions. The company is focused on creating advanced technologies that enhance the precision and safety of eye surgeries, particularly in the treatment of conditions such as cataracts and glaucoma.
Lios’s proprietary platform technology offers a novel approach to surgical procedures, aiming to improve visual outcomes for patients and reduce the burden on healthcare systems. The EIC grant will support Lios in accelerating their product development, conducting further validation studies, and building out their commercialization strategy. This recognition from the EIC signifies a major milestone for Lios, propelling their innovative ophthalmic technologies towards wider adoption and positive patient impact.
This dual success for CroíValve and Lios marks a significant achievement for the Irish innovation ecosystem. It reflects the country’s commitment to fostering a vibrant research and development environment and nurturing companies with the potential to make a real difference in global healthcare. The EIC Accelerator funding provides these promising companies with the crucial resources needed to transform their visionary ideas into tangible solutions that can improve patient outcomes and address significant healthcare challenges. Both companies are poised to make substantial contributions to their respective fields, and this European backing will undoubtedly play a vital role in their future success.
Dublin’s CroíValve and Lios bag €18.75m in EIC accelerator funds
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Silicon Republic published ‘Dublin’s CroíValve and Lios bag €18.75m in EIC accelerator funds’ at 2025-07-01 10:44. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.